INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 December 2018
Net Assets |
£209m |
Net Assets per share |
556p |
Share price |
570p |
Total value of unquoted investments |
£30m |
Total number of portfolio companies |
61 |
Dividend |
4% of NAV per annum |
Top Ten Quoted Investments
Company Name |
% NAV |
Incyte |
6.1 |
Vertex |
5.6 |
Celgene |
5.4 |
Genmab |
5.1 |
Gilead Sciences |
5.0 |
Regeneron |
4.4 |
Exelixis |
4.4 |
Illumina |
3.8 |
Neurocrine |
3.4 |
Biomarin |
3.0 |
|
----------- |
Total |
46.2 |
Geographical Allocation |
% NAV |
US & Canada |
87 |
Europe |
13 |
|
----------- |
Total |
100 |
Quoted/Unquoted Allocation |
% NAV |
Quoted |
85 |
Unquoted |
15 |
|
----------- |
Total |
100 |
NAV % Market Cap |
% NAV |
Large Cap >USD10BN |
44 |
Mid Cap =USD1-10BN |
33 |
Small Cap <USD1BN |
23 |
|
----------- |
Total |
100 |
NAV % by Therapeutic Areas |
% NAV |
Oncology |
35 |
Rare diseases |
21 |
CNS |
10 |
Ophthalmology |
5 |
Infectious Diseases |
5 |
Tools |
4 |
Inflammation |
3 |
Medtech |
3 |
Metabolic |
0 |
Other |
14 |
|
----------- |
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
17 JANUARY 2019